Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Generic of Sensipar:...

    Generic of Sensipar: US court denies Amgen request for preliminary injunction against Cipla

    Farhat NasimWritten by Farhat Nasim Published On 2019-05-04T09:45:42+05:30  |  Updated On 4 May 2019 9:45 AM IST
    Generic of Sensipar: US court denies Amgen request for preliminary injunction against Cipla

    Cipla's cinacalcet hydrochloride tablets in the strengths of 30mg, 60mg and 90mg are generic versions of Sensipar, a branded drug marketed by Amgen Inc.


    New Delhi: Pharma major Cipla Friday said the US District Court of Delaware has denied Amgen Inc's request for a preliminary injunction to stop Cipla's continued sale of its generic cinacalcet hydrochloride tablets in the US market.


    The preliminary injunction is a court order made in the early stages of a lawsuit that prohibits the parties from doing an act in order to preserve the status quo until the trial is over and the court has issued a ruling or judgment.


    Read Also:Cipla gets USFDA nod for Ambrisentan tablets to treat pulmonary arterial hypertension


    The company had announced a phased launch of generic cinacalcet hydrochloride tablets, used in the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis, in the US market in a regulatory filing in March this year.


    The launch, however, is a subject of ongoing litigation, it had added.


    Read Also: Dr Reddys, Cipla arm recall drugs in US; includes 7.8 lakh vials of Testosterone Cypionate injection


    "... Chief Judge Stark of the US District Court of Delaware denied Amgen, Inc's request for a preliminary injunction to stop Cipla's continued sale of its generic cinacalcet hydrochloride tablets 30mg, 60mg, 90mg in the USA," Cipla said in a filing to BSE.


    Cipla's cinacalcet hydrochloride tablets in the strengths of 30mg, 60mg and 90mg are generic versions of Sensipar, a branded drug marketed by Amgen Inc.


    Read Also: Cipla appoints Dr Raju Mistry as Global Chief People Officer

    AmgenAmgen IncBSEChief Judge StarkCinacalcetcinacalcet hydrochlorideCipladialysisgeneric cinacalcet hydrochloride tabletsgeneric versions of SensiparhyperparathyroidismNew Delhipharma major Ciplapreliminary injunctionSensiparshares of ciplatreatmentUS District CourtUSA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok